Myrexis Quick Ratio (MYRX) starting from the fourth quarter 2013 to fourth quarter 2012, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Myrexis, Inc.  (MYRX)

Myrexis's Quick Ratio

MYRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Myrexis's Cash & cash equivalent, this led to improvement in Myrexis's Quick Ratio to 16.35, Quick Ratio remained below Myrexis, Inc. average.

Within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Quick Ratio than Myrexis in fourth quarter 2013. While Quick Ratio total ranking in the fourth quarter 2013 has deteriorated compared to the prior quarter from 147 to 319.

Explain Quick Ratio?
How much Cash & cash equivalents MYRX´s has?
What are MYRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYRX Quick Ratio (Jun 30 2013)
Q4		 (Mar 31 2013)
Q3		 (Dec 31 2012)
Q2		 (Sep 30 2012)
Q1		 (Jun 30 2012)
Q4
Y / Y Current Liabilities Change -96.75 % -93.82 % -56.27 % -52.51 % -40.82 %
Y / Y Cash & cash equivalent Change -98.63 % -97.78 % 0.76 % -16.16 % -16.34 %
Quick Ratio MRQ 16.35 4.39 62.21 55.45 38.78
MYRX's Total Ranking # 319 # 147 # 148 # 128 # 0
Seq. Current Liabilities Change -78.55 % -73.6 % -14.07 % -33.26 % -59.21 %
Seq. Cash & cash equivalent Change -20.08 % -98.14 % -3.58 % -4.57 % 29.59 %



Quick Ratio fourth quarter 2013 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 36
Overall Market # 319


Quick Ratio Statistics
High Average Low
62.21 30.58 4.39
(Dec 31 2012)   (Mar 31 2013)




Financial Statements
Myrexis's Current Liabilities $ 0 Millions Visit MYRX's Balance sheet
Myrexis's Cash & cash equivalent $ 1 Millions Visit MYRX's Balance sheet
Source of MYRX's Sales Visit MYRX's Sales by Geography


Cumulative Myrexis's Quick Ratio

MYRX's Quick Ratio for the trailling 12 Months

MYRX Quick Ratio

 (Jun 30 2013)
12 Months		 (Mar 31 2013)
12 Months		 (Dec 31 2012)
12 Months		 (Sep 30 2012)
12 Months		 (Jun 30 2012)
12 Months
Y / Y Current Liabilities TTM Growth -76.9 % -65.12 % 6.48 % 75.45 % 265.05 %
Y / Y Cash & cash equivalent TTM Growth -50.17 % -28.04 % 12.3 % 55.95 % 219.85 %
Quick Ratio TTM 51.86 46.87 30.13 25.99 24.03
Total Ranking TTM # 454 # 482 # 0 # 0 # 0
Seq. Current Liabilities TTM Growth -40.44 % -49.02 % -13.59 % -11.96 % -10.06 %
Seq. Cash & cash equivalent TTM Growth -34.11 % -20.7 % 0.19 % -4.81 % -4.86 %

Quick ratio ranking by company, industry and sector >> Back to MYRX Financial Strength Comparisons >> Go to Compare MYRX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Myrexis's average Cash & cash equivalent, this led to increase in in Myrexis's Quick Ratio to 51.86, above MYRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Quick Ratio than Myrexis. While Quick Ratio overall ranking has improved so far to 454, from total ranking during the twelve months ending third quarter 2013 at 482.

Explain Quick Ratio?
How much Cash & cash equivalents MYRX´s has?
What are MYRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 16
Healthcare Sector # 69
Within the Market # 454


trailing twelve months Quick Ratio Statistics
High Average Low
51.86 49.36 46.87
(Jun 30 2013)   (Mar 31 2013)




Companies with similar Quick Ratio in the quarter ending Jun 30 2013, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2013 MRQ Cash & cash equivalentJun 30 2013 MRQ Current Liabilities
Momenta Pharmaceuticals inc   17.84 $ 300.160  Millions$ 16.829  Millions
Applied Genetic Technologies Corporation  16.78 $ 22.893  Millions$ 1.364  Millions
Myrexis, Inc.  16.35 $ 1.210  Millions$ 0.074  Millions
Nutrastar International Inc.  16.13 $ 87.848  Millions$ 5.448  Millions
Chelsea Therapeutics International, Ltd.  14.45 $ 22.012  Millions$ 1.523  Millions
Receptos, Inc.  12.36 $ 91.146  Millions$ 7.376  Millions
Aevi Genomic Medicine, Inc.  12.35 $ 28.979  Millions$ 2.347  Millions
Fresh Tracks Therapeutics Inc   11.14 $ 67.498  Millions$ 6.059  Millions
China Biologic Products Holdings Inc   11.07 $ 152.681  Millions$ 13.797  Millions
Curis Inc   10.65 $ 57.148  Millions$ 5.365  Millions
Neurocrine Biosciences Inc   10.55 $ 153.696  Millions$ 14.573  Millions
Bio techne Corp  10.38 $ 332.937  Millions$ 32.084  Millions
Bluebird Bio Inc   8.49 $ 228.847  Millions$ 26.949  Millions
Sangamo Therapeutics Inc   6.70 $ 47.276  Millions$ 7.055  Millions
La Jolla Pharmaceutical Company  5.98 $ 1.842  Millions$ 0.308  Millions
Repligen Corp  5.69 $ 58.145  Millions$ 10.219  Millions
Cardiff Oncology Inc   5.68 $ 8.302  Millions$ 1.462  Millions
Viskase Holdings inc   5.56 $ 14.457  Millions$ 2.600  Millions
Aceragen Inc   5.49 $ 16.612  Millions$ 3.024  Millions
Trius Therapeutics Inc  5.45 $ 69.723  Millions$ 12.801  Millions
Compugen Ltd  5.33 $ 32.921  Millions$ 6.181  Millions
Vaxart Inc   5.18 $ 66.800  Millions$ 12.900  Millions
Exelixis Inc   4.88 $ 364.186  Millions$ 74.600  Millions
Amgen Inc   4.60 $ 22,018.000  Millions$ 4,784.000  Millions
Sorrento Therapeutics Inc   3.88 $ 5.755  Millions$ 1.484  Millions
Pluri Inc   3.84 $ 22.764  Millions$ 5.921  Millions
Seagen Inc   3.74 $ 338.089  Millions$ 90.348  Millions
Palisade Bio Inc   3.71 $ 11.166  Millions$ 3.006  Millions
Novavax inc   3.61 $ 40.599  Millions$ 11.256  Millions
Telik Inc  3.54 $ 4.412  Millions$ 1.247  Millions

Date modified: 2026-07-10T08:33:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.